Disopyramide
| Disopyramide | |
|---|---|
| Salts [] | |
|---|---|
| Disopyramide phosphate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 339.50 g/mol [1] |
| Melting point | 94.5-95 °C [1] |
| Solubility | 44.9 mg/L [1] |
| Predicted LogP | 3.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C21H29N3O |
| IUPAC name | 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide |
| SMILES | CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C |
| InChI | InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25) |
| InChIKey | UVTNFZQICZKOEM-UHFFFAOYSA-N |
| CAS number | 3737-09-5 |
| UNII | GFO928U8MQ |
| PubChem CID | 3114 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 6.7 hours (range 4–10 hours) |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Excretion | Renal (80%) |
| Routes of administration | Oral, intravenous |
Disopyramide (also known as Dicorantil, Lispine, Disopiramida, Isorythm, Rythmodan P, Disopyramidum, Ritmilen, Dl-disopyramide, Searle-703 or Sc-7031) is a sodium channel blocker substance of the phenylpropylamine and amphetamine class.
Chemistry
Salts []
Stereochemistry []
Disopyramide is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Disopyramide matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- cardiac therapy (C01)
- antiarrhythmics, class i and iii (C01B)
- antiarrhythmics, class ia (C01BA)
- (C01BA03)
- disopyramide (C01BA03)
MeSH Classification
Mechanism of action []
Disopyramide is a Type 1A antiarrhythmic drug (ie, similar to procainamide and quinidine). It inhibits the fast sodium channels. In animal studies Disopyramide decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | induction / metabolism / inhibition | 95 (3 contraindicated) |
|---|---|---|
| SCN10A | shared target | 8 (1 contraindicated) |
| SCN11A | shared target | 8 (1 contraindicated) |
| SCN1A | shared target | 8 (1 contraindicated) |
| SCN2A | shared target | 8 (1 contraindicated) |
| SCN3A | shared target | 8 (1 contraindicated) |
| SCN4A | shared target | 8 (1 contraindicated) |
| SCN5A | shared target | 8 (1 contraindicated) |
| SCN8A | shared target | 8 (1 contraindicated) |
| SCN9A | shared target | 8 (1 contraindicated) |
Medical side effects []
106 side effects listed on drug labels in SIDER 4.1 (disopyramide).
- Dry mouth
- Urinary hesitation
- Constipation
- Urinary retention
- Acute retention of urine
- Agranulocytosis
- Angioedema
- Decreased appetite
- Apnoea
- Atrioventricular block
- Block heart
- Bundle branch block
- Cardiac output decreased
- Chest pain
- Coma
- Confusional state
- Feeling abnormal
- Malaise
- Cyanosis
- Depression
- Diarrhoea
- Diplopia
- Dizziness
- Syncope
- Somnolence
- Dyspepsia
- Dyspnoea
- Dysuria
- Oedema
- Dermatitis
- Rash
- Asthenia
- Fatigue
- Body temperature increased
- Flatulence
- Abdominal bloating
- Gynaecomastia
- Headache
- Cardiac arrest
- Cardiac failure
- Cardiac failure congestive
- Hepatitis
- Hypercholesterolaemia
- Hypoglycaemia
- Hypokalaemia
- Hypotension
- Jaundice cholestatic
- Mydriasis
- Nausea
- Nervousness
- Tension
- Neutropenia
- Hypoaesthesia
- Sensory loss
- Pain
- Ache
- Pallor
- Paraesthesia
- Tingling sensation
- Pruritus
- Psychotic disorder
- Shock
- Cardiogenic shock
- Skin disorder
- Loss of consciousness
- Thrombocytopenia
- Torsade de pointes
- Pollakiuria
- Urticaria
- Ventricular fibrillation
- Ventricular tachycardia
- Vertigo
- Vomiting
- Weight increased
- Dissociation
- Blood urea increased
- Blood creatinine increased
- Muscular weakness
- Accommodation disorder
- Haemoglobin decreased
- Discomfort
- Ill-defined disorder
- Nasal dryness
- Cardiac fibrillation
- Nodal rhythm
- Abdominal pain upper
- Rash morbilliform
- Hepatic enzyme increased
- Erectile dysfunction
- Prostatism
- Defect conduction intraventricular
- Acute psychosis
- Dry eye
- Vision blurred
- Systemic lupus erythematosus
- Bradycardia
- Electrocardiogram QRS complex
- Rash generalised
- Sinus arrest
- Dysgeusia
- Feeling hot
- Hyperhidrosis
- Poisoning
- Arrhythmia
- Insomnia
- Abdominal distension
Indications
- Arrhythmia
- Atrioventricular block complete
- Atrioventricular block first degree
- Bundle branch block
- Bundle branch block right
- Cardiac disorder
- Cardiomyopathy
- Conduction disorder
- Decompensation cardiac
- Depressed mood
- Electrocardiogram QT prolonged
- Excitability
- Glaucoma
- Hemiblock NOS
- Hepatic impairment
- Hepatic insufficiency
- Hypersensitivity
- Infarction
- Ischaemia
- Myocardial infarction
- Proarrhythmia
- Renal failure
- Renal impairment
- Shock
- Sinoatrial node dysfunction
- Sudden death
- Sustained ventricular tachycardia
- Ventricular arrhythmia
Legal status []
- Brazil: Disopyramide is a C1.[3]
- United Kingdom: Disopyramide is Prescription only.
- United States: Disopyramide is Prescription only.
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3114, Disopyramide. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3114
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Disopyramide. UNII: GFO928U8MQ. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/GFO928U8MQ
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União [Official Diary of the Union]. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 11:39:50 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 11:39:46 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 11:39:46 |
| gsrs | ok | 2026-11-20 11:39:47 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014425) | 2026-11-20 11:39:46 |
| kegg | ok | 2026-11-20 11:39:49 |
| pubchem | ok | 2026-11-20 11:39:44 |
| missing (no r/tripreports posts mention it) | 2026-11-20 11:39:46 | |
| sider | ok | 2026-11-20 11:39:46 |
| structure | ok | 2026-11-20 11:39:46 |
| wikipedia | ok | 2026-11-20 11:39:46 |